Dr. Lal PathLabs Subsidiary Acquires Remaining 30% in Centrapath Labs
Dr. Lal PathLabs Ltd announced that its wholly-owned subsidiary, PathLabs Unifiers Private Limited (PUPL), has acquired the remaining 30% equity stake in Centrapath Labs Private Limited (CPL) on October 13, 2026. Following this acquisition, CPL has now become a wholly-owned subsidiary of PUPL. The acquisition was completed for a cash consideration, with 30% equity shares of CPL acquired at INR 1608.352 per share. CPL, incorporated in 2019, operates in the Healthcare/Diagnostics Services sector. Its turnover for FY2026 was ₹20.5 Crores, down from ₹23.7 Crores in FY2025 and ₹20.8 Crores in FY2024. This move consolidates CPL's ownership under PUPL, strengthening the group's control over its diagnostic services.
Key Highlights
- PUPL acquired the remaining 30% stake in subsidiary CPL.
- CPL is now a wholly-owned subsidiary of PUPL.
- Acquisition completed for cash consideration at ₹1608.352 per share.
- CPL's FY26 turnover was ₹20.5 Crores.
- Transaction is not a related party transaction.
Price Impact
More from LALPATHLAB